Medical Oncology

, 30:338 | Cite as

Delayed response and survival from NovoTTF-100A in recurrent GBM

  • J. Lee Villano
  • Leena E. Williams
  • Karriem S. Watson
  • Nandini Ignatius
  • Marquess T. Wilson
  • Tibor Valyi-Nagy
  • Edward A. Michals
  • Herbert H. Engelhard
Short Communication

Abstract

We present a 48-year-old male with recurrent glioblastoma (GBM) who was enrolled in the NovoTTF-100A landmark phase III study and has been on device for >6 years. During this time, his magnetic resonance images demonstrated initial growth followed by a slow decrease in enhancement with continued residual disease. Long-term survivors in patients with recurrent GBM are rare, especially in the absence of definitive local treatment such as surgery or radiosurgery. We present the clinical, imaging and pathological findings for this patient in relation to use of the NovoTTF-100A device.

Keywords

Glioblastoma Brain tumor Tumor treatment fields Recurrent tumor Survival 

References

  1. 1.
    Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27:4733–40.PubMedCrossRefGoogle Scholar
  2. 2.
    Valery CA, Seilhean D, Boyer O, Marro B, Hauw JJ, Kemeny JL, et al. Long-term survival after gene therapy for a recurrent glioblastoma. Neurology. 2002;58:1109–12.PubMedCrossRefGoogle Scholar
  3. 3.
    Sperduto CM, Chakravarti A, Aldape K, Burger P, Papermaster GB, Sperduto P. Twenty-year survival in glioblastoma: a case report and molecular profile. Int J Radiat Oncol Biol Phys. 2009;75:1162–5.PubMedCrossRefGoogle Scholar
  4. 4.
    Combs SE, Thilmann C, Edler L, Debus J, Schulz-Ertner D. Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single institution. J Clin Oncol. 2005;23:8863–9.PubMedCrossRefGoogle Scholar
  5. 5.
    Sonoda Y, Kumabe T, Watanabe M, Nakazato Y, Inoue T, Kanamori M, et al. Long-term survivors of glioblastoma: clinical features and molecular analysis. Acta Neurochir. 2009;151:1349–58.PubMedCrossRefGoogle Scholar
  6. 6.
    Stupp R, Wong ET, Kanner AA, Steinberg D, Engelhard H, Heidecke V, et al. NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer. 2012.Google Scholar
  7. 7.
    Louis DN, International Agency for Research on Cancer, World Health Organization, Deutsches Krebsforschungszentrum Heidelberg. WHO classification of tumours of the central nervous system. Lyon Geneva, Switzerland: International Agency for Research on Cancer, Distributed by WHO Press, World Health Organization; 2007. p. 309.Google Scholar
  8. 8.
    Ruben JD, Dally M, Bailey M, Smith R, McLean CA, Fedele P. Cerebral radiation necrosis: incidence, outcomes, and risk factors with emphasis on radiation parameters and chemotherapy. Int J Radiat Oncol Biol Phys. 2006;65:499–508.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • J. Lee Villano
    • 1
    • 2
    • 6
  • Leena E. Williams
    • 2
  • Karriem S. Watson
    • 2
  • Nandini Ignatius
    • 1
  • Marquess T. Wilson
    • 3
  • Tibor Valyi-Nagy
    • 4
  • Edward A. Michals
    • 5
  • Herbert H. Engelhard
    • 2
  1. 1.Department of MedicineUniversity of Illinois Medical CenterChicagoUSA
  2. 2.Department of NeurosurgeryUniversity of Illinois Medical CenterChicagoUSA
  3. 3.Department of NeurologyUniversity of Illinois Medical CenterChicagoUSA
  4. 4.Department of PathologyUniversity of Illinois Medical CenterChicagoUSA
  5. 5.Department of RadiologyUniversity of Illinois Medical CenterChicagoUSA
  6. 6.University of KentuckyLexingtonUSA

Personalised recommendations